Real-life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA.
Mobile health technology
nasal polyp
patient-reported outcome measure
real-world evidence
visual analogue scale
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
30
10
2019
revised:
27
03
2020
accepted:
03
04
2020
pubmed:
20
5
2020
medline:
15
5
2021
entrez:
20
5
2020
Statut:
ppublish
Résumé
Chronic rhinosinusitis (CRS) is a chronic inflammatory disease associated with a substantial personal and socioeconomic burden. Monitoring of patient-reported outcomes by mobile technology offers the possibility to better understand real-life burden of CRS. This study reports on the cross-sectional evaluation of data of 626 users of mySinusitisCoach (mSC), a mobile application for CRS patients. Patient characteristics of mSC users were analysed as well as the level of disease control based on VAS global rhinosinusitis symptom score and adapted EPOS criteria. The mSC cohort represents a heterogeneous group of CRS patients with a diverse pattern of major symptoms. Approximately half of patients reported nasal polyps. 47.3% of all CRS patients were uncontrolled based on evaluation of VAS global rhinosinusitis symptom score compared to 40.9% based on adapted EPOS criteria. The impact of CRS on sleep quality and daily life activities was significantly higher in uncontrolled versus well-controlled patients. Half of patients had a history of FESS (functional endoscopic sinus surgery) and reported lower symptom severity compared to patients without a history of FESS, except for patients with a history of more than 3 procedures. Patients with a history of FESS reported higher VAS levels for impaired smell. Real-life data confirm the high disease burden in uncontrolled CRS patients, clearly impacting quality of life. Sinus surgery improves patient-reported outcomes, but not in patients with a history of more than 3 procedures. Mobile technology opens a new era of real-life monitoring, supporting the evolution of care towards precision medicine.
Sections du résumé
BACKGROUND
Chronic rhinosinusitis (CRS) is a chronic inflammatory disease associated with a substantial personal and socioeconomic burden. Monitoring of patient-reported outcomes by mobile technology offers the possibility to better understand real-life burden of CRS.
METHODS
This study reports on the cross-sectional evaluation of data of 626 users of mySinusitisCoach (mSC), a mobile application for CRS patients. Patient characteristics of mSC users were analysed as well as the level of disease control based on VAS global rhinosinusitis symptom score and adapted EPOS criteria.
RESULTS
The mSC cohort represents a heterogeneous group of CRS patients with a diverse pattern of major symptoms. Approximately half of patients reported nasal polyps. 47.3% of all CRS patients were uncontrolled based on evaluation of VAS global rhinosinusitis symptom score compared to 40.9% based on adapted EPOS criteria. The impact of CRS on sleep quality and daily life activities was significantly higher in uncontrolled versus well-controlled patients. Half of patients had a history of FESS (functional endoscopic sinus surgery) and reported lower symptom severity compared to patients without a history of FESS, except for patients with a history of more than 3 procedures. Patients with a history of FESS reported higher VAS levels for impaired smell.
CONCLUSION
Real-life data confirm the high disease burden in uncontrolled CRS patients, clearly impacting quality of life. Sinus surgery improves patient-reported outcomes, but not in patients with a history of more than 3 procedures. Mobile technology opens a new era of real-life monitoring, supporting the evolution of care towards precision medicine.
Identifiants
pubmed: 32424899
doi: 10.1111/all.14408
pmc: PMC7687134
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2867-2878Informations de copyright
© 2020 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Clin Transl Allergy. 2018 Sep 3;8:32
pubmed: 30186592
Rhinology. 2016 Jun;54(2):117-28
pubmed: 26934470
Clin Transl Allergy. 2017 Dec 27;7:49
pubmed: 29299230
Allergy. 2019 Dec;74(12):2312-2319
pubmed: 31090937
Allergy. 2017 Sep;72(9):1297-1305
pubmed: 28306159
Allergy. 2017 Feb;72(2):274-281
pubmed: 27590749
J Allergy Clin Immunol. 2013 Jan;131(1):110-6.e1
pubmed: 23021878
Am J Rhinol Allergy. 2011 Jul-Aug;25(4):205-8
pubmed: 21819754
Rhinology. 2019 Feb 1;57(1):32-42
pubmed: 29911211
Otolaryngol Head Neck Surg. 2016 Dec;155(6):936-948
pubmed: 27576679
Rhinol Suppl. 2017 Mar;54(26):1-30
pubmed: 29528615
World Allergy Organ J. 2014 Oct 27;7(1):25
pubmed: 25379119
Allergy. 2011 Sep;66(9):1216-23
pubmed: 21605125
Int Forum Allergy Rhinol. 2019 Apr;9(4):402-408
pubmed: 30570840
Allergy. 2020 Nov;75(11):2867-2878
pubmed: 32424899
Rhinol Suppl. 2012 Mar;23:3 p preceding table of contents, 1-298
pubmed: 22764607
J Allergy Clin Immunol. 2011 Nov;128(5):989-95.e1-8
pubmed: 21958585
J Allergy Clin Immunol. 2016 May;137(5):1449-1456.e4
pubmed: 26949058
Laryngoscope. 2017 Mar;127(3):550-555
pubmed: 27859303
Clin Transl Allergy. 2019 Aug 30;9:43
pubmed: 31497279
Rhinology. 2014 Mar;52(1):3-8
pubmed: 24618621
Allergy. 2019 Jul;74(7):1292-1306
pubmed: 30644567
Allergy. 2012 Jan;67(1):91-8
pubmed: 22050239
Rhinology. 2018 Sep 1;56(3):209-215
pubmed: 29466477
Lancet. 2019 Nov 2;394(10209):1638-1650
pubmed: 31543428
Allergy. 2017 Jun;72(6):857-865
pubmed: 28072463
Rhinology. 2017 Sep 1;55(3):202-210
pubmed: 28501885
J Allergy Clin Immunol. 2016 May;137(5):1347-58
pubmed: 27155030
Clin Exp Allergy. 2017 Dec;47(12):1526-1533
pubmed: 28886234
Laryngoscope. 2017 Feb;127(2):309-320
pubmed: 27873345
Am J Rhinol Allergy. 2009 Mar-Apr;23(2):145-8
pubmed: 19401038
Clin Transl Allergy. 2019 Jun 14;9:30
pubmed: 31249662
Clin Transl Allergy. 2017 Jul 12;7:22
pubmed: 28706720
JAMA. 2016 Feb 2;315(5):469-79
pubmed: 26836729
Allergy. 2017 Feb;72(2):282-290
pubmed: 27392210